Question special

Given that the 14 sites did not use procalcitonin in routine care before the trial began, I'm curious if any of the sites have since picked procalcitonin up as a routinely available lab? Or if any had it become routinely available during the trial?

The discussion briefly touched on how the site difference could have contributed to the discrepancy between ProACT and previous trials of procalcitonin-guided antibiotic prescription. I'm curious if the results would be different at a site(s) that already routinely uses procalcitonin, and if adherence would be higher, especially in the <0.1 procalcitonin group.

Huge thanks to everyone involved in this Journal Club. Very exciting.